2013-04-16 05:59:57 -
/EINPresswire.com/ FOR IMMEDIATE RELEASE
Hershey, PA, & Rockville, MD April 10th, 2013 – Immunomic Therapeutics, Inc., (“ITI,” Hershey, PA), a leader in developing novel allergy immunotherapies, announced today the nomination of Bernard C. Rudnick to its Board of Directors. The nomination of Mr. Rudnick to the Board occurs at a pivotal time for ITI, having recently completed its first-in-man Phase I clinical study for JRC-LAMP-vax.
“Bernard C. Rudnick has extensive experience in start-ups, a long track record and success in biotech ventures. His history of exceptional corporate governance is
a great asset for Immunomic Therapeutics, now that we are a clinical stage biotechnology company”, remarked Bill Hearl, ITI’s Founder and CEO.
Mr. Rudnick is founder and managing partner of CapGenic Advisors, LLC He brings over 36 years of experience in executive-level strategy, finance, and management. He has extensive knowledge in merger, acquisition, capital formation and licensing leadership with companies ranging from start-up to Fortune 50. He currently advises companies in the clinical software space, therapeutic, medical device, and in the cell line engineering areas. His advisory clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), Kika Clinical Solutions (now MRGE) as well as a number of early stage life sciences companies.
Currently, Mr. Rudnick is a director of Otosound, Benten Bioservices, director and CFO of Immunomic Therapeutics, CFO and Director of Genomic Expression. He founded one of the nation’s leading entrepreneurial programs (MADV) at the Fox School of Business, and is an active member of several syndicated angel capital groups. Mr. Rudnick’s entrepreneurial career includes a number of startups, three of which grew to over $60 million in revenue before exiting. He has been instrumental in companies’ successes, and has raised over $700 million for biotechnology companies.
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company with lab facilities in Rockville, MD and process-development plant in Hershey, PA. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases. For more information about ITI and LAMP Technology please visit www.immunomix.com.
x x x
Dr. Bill Hearl, President / CEO
Immunomic Therapeutics, Inc.
1214 Research Blvd, Suite 201
Hershey, PA 17036
Press Release: B Rudnick nominated to BOD